Anatomo-radiological correlation in breast cancer response to neoadjuvant chemotherapy according to histological and molecular subtypes.

Congress:

ECR 2021

Poster Number:

C-10320

Type:

Scientific Exhibit

Keywords:

Breast, MR, Treatment effects, Cancer, Molecular, genomics and proteomics, Multidisciplinary cancer care

Authors:

I. Mendoza Arnau, M. D. Rabadán Caravaca, M. Culiañez Casas, S. Martínez Meca; Granada/ES

DOI:

10.26044/ecr2021/C-10320

DOI-Link:

https://dx.doi.org/10.26044/ecr2021/C-10320

Purpose

To evaluate the response to neoadjuvant chemotherapy according to the histological and molecular subtypes of breast cancer. To correlate the radiological response after neoadjuvant chemotherapy with the pathologic response after surgery according to the molecular subtype.

Methods and materials

We have performed a descriptive and retrospective study including 103 women with breast cancer who were candidates for treatment with neoadjuvant chemotherapy in our hospital between October 2017 and August 2019. Breast MRI was performed for staging and 15 days after systemic neoadjuvant treatment. All patients underwent surgery after neoadjuvant treatment and histologic examination of the surgical piece was performed. The information about each procedure was communicated to every patient and they signed the informed consent. Breast MRI was performed on a 1.5 T equipment...

Results

The mean age of the patients was 54.2 years. The most common histological subtype was infiltrating ductal carcinoma (92 cases, 90.29%) followed by infiltrating lobular carcinoma (6 cases, 5.83%), mucinous carcinoma (3 cases, 2.91%) and solid intraductal carcinoma (1 case, 0.97%). Regarding molecular subtypes, the most common was luminal B HER2- (39 cases, 37.86%) followed by triple negative (TN) (24 cases, 23.33%), luminal B HER2 + (17 cases, 16.50%), HER2 (2 cases, 11.65%) and Luminal A (11 cases, 10.68%) (Fig. 9) Radiological response (Fig.10A): -...

Conclusion

Breast MRI is an effective tool in assessing the response to neoadjuvant chemotherapy treatment in patients with HER2, luminal B HER +, and TN molecular subtypes of breast cancer.

Personal information and conflict of interest

I. Mendoza Arnau: Nothing to disclose M. D. Rabadán Caravaca: Nothing to disclose M. Culiañez Casas: Nothing to disclose S. Martínez Meca: Nothing to disclose

References

Claudette E, Loo M,Straver E. Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype. J Clin Oncol. 2011 Feb 20;29(6):660-6. Gu YL, Pan SM, Ren J. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis. Clin Breast Cancer.2017 Jul;17(4): 245-255 Lobbes MB, Prevos R, Smidt M.The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy:a...

Fig 1: Fig. 1. Radiological response in MRI assessment to neoadjuvant chemotherapy...

Fig 2: Fig. 2. Complete response: absence of enhancement in subtraction sequences...

Fig 3: Fig. 3. Concentric morphological response: circumferential decreasing from the...

Fig 4: Fig. 4. Concentric morphological response: tumor decreases from the periphery...

Fig 5: Fig. 5. Mixed morphological response. Decreasing of the tumor from the...

Fig 6: Fig. 6. Pre- NAC breast MRI (A): BI-RADS 6 lesion with type 2 signal intensity...

Fig 7: Fig. 7. Complete radiological response corresponding to a grade 5 of pathologic...

Fig 8: Fig. 8. Minor partial radiological response corresponding to a grade 1 of...

Fig 9: Fig. 9. Percentage of histological and molecular subtypes.

Fig 10: Fig. 10. Percentaje of radiological (A) and pathologic response (B).

Fig 11: Fig. 11. Correlation between radiological and pathologic response according to...